Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

MGT Capital Investments Regains NYSE MKT Listing Compliance



  MGT Capital Investments Regains NYSE MKT Listing Compliance

Business Wire

HARRISON, N.Y. -- December 10, 2012

MGT Capital Investments, Inc. (NYSE MKT: MGT) announced today receipt of a
letter from NYSE Regulation dated December 6, 2012. In the letter, the Company
was informed that based upon review of publicly available information,
including MGT filings with the Securities and Exchange Commission, the Company
has resolved the continued listing deficiency with respect to Sections
1003(a)(i), (ii) and (iii) of the NYSE MKT LLC Company Guide referenced in the
Exchange’s letter dated June 8, 2011, as previously reported. As with the case
for all listed issuers, the Company's continued listing eligibility will
continue to be assessed on an on-going basis.

About MGT Capital Investments, Inc.

MGT and its subsidiaries are engaged in the business of acquiring and
monetizing intellectual property rights. MGT Gaming, Inc., a majority-owned
subsidiary, owns U. S. Patent No. 7,892,088 that relates to casino gaming
systems. In November 2012, MGT Gaming filed a patent infringement suit
against Caesars Entertainment Corporation (NASDAQ GS: CZR), MGM Resorts
International, Inc. (NYSE: MGM), WMS Gaming - a subsidiary of WMS Industries,
Inc. (NYSE: WMS), Penn National Gaming, Inc. (NASDAQ GS: PENN), and Aruze
Gaming America, Inc. In addition, the Company owns Medicsight, Inc., a medical
technology company with patent ownership, as well as operations in imaging
software and hardware devices. The company's computer-aided detection software
assists radiologists with detection of colorectal polyps, and has received
regulatory approvals including CE Mark and U. S. FDA clearance.

Forward looking statements

This press release contains forward-looking statements. The words or phrases
"would be," "will allow," "intends to," "will likely result," "are expected
to," "will continue," "is anticipated," "estimate," "project," or similar
expressions are intended to identify "forward-looking statements." MGT's
financial and operational results reflected above should not be construed by
any means as representative of the current or future value of its common
stock. All information set forth in this news release, except historical and
factual information, represents forward-looking statements. This includes all
statements about the Company's plans, beliefs, estimates and expectations.
These statements are based on current estimates and projections, which involve
certain risks and uncertainties that could cause actual results to differ
materially from those in the forward-looking statements. These risks and
uncertainties include issues related to: rapidly changing technology and
evolving standards in the industries in which the Company and its subsidiaries
operate; the ability to obtain sufficient funding to continue operations,
maintain adequate cash flow, profitably exploit new business, license and sign
new agreements; the unpredictable nature of consumer preferences; and other
factors set forth in the Company's most recently filed annual report and
registration statement. Readers are cautioned not to place undue reliance on
these forward-looking statements, which reflect management's analysis only as
of the date hereof. The Company undertakes no obligation to publicly revise
these forward-looking statements to reflect events or circumstances that arise
after the date hereof. Readers should carefully review the risks and
uncertainties described in other documents that the Company files from time to
time with the U.S. Securities and Exchange Commission.

Contact:

Company contact:
MGT Capital Investments, Inc.
Robert Traversa, Chief Financial Officer
914-630-7431
rtraversa@mgtci.com
or
Investor contact for MGT Capital Investments, Inc.
The Del Mar Consulting Group, Inc.
Robert B. Prag, President, 858-794-9500
858-361-1786
bprag@delmarconsulting.com
or
Alex Partners, LLC
Scott Wilfong, President, 425-242-0891
scott@alexpartnersllc.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement